Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study
Jingjing Wu(Beijing Tian Tan Hospital), Mingzhi Zhang(Chinese Academy of Sciences), Shanshan Ma(First Affiliated Hospital of Zhengzhou University), Linan Zhu(First Affiliated Hospital of Zhengzhou University), Xiaolong Wu(First Affiliated Hospital of Zhengzhou University), Songtao Niu(First Affiliated Hospital of Zhengzhou University), Jieming Zhang(Lymphoma Research Foundation), Xin Li(Hubei University of Medicine), Xinhua Wang(Zhengzhou University), Xudong Zhang(Southwest University of Science and Technology), Meng Dong(First Affiliated Hospital of Zhengzhou University), Lei Zhang(First Affiliated Hospital of Zhengzhou University), Wenhua Wang(Lanzhou University), Jiaqin Yan(First Affiliated Hospital of Zhengzhou University), Zhenchang Sun(First Affiliated Hospital of Zhengzhou University), Hui Yu(University of Colorado Anschutz Medical Campus), Xiaorui Fu(First Affiliated Hospital of Zhengzhou University), Yu Chang(Jilin University), Feifei Nan(First Affiliated Hospital of Zhengzhou University), Ling Li(First Affiliated Hospital of Zhengzhou University), Zhi‐Yuan Zhou(Tsinghua University), Mengjie Ding(First Affiliated Hospital of Zhengzhou University), Zhaoming Li(First Affiliated Hospital of Zhengzhou University)
Cited by 44
Related Papers
New loci for body fat percentage reveal link between adiposity and cardiometabolic disease risk
|Nature Communications|2016|318
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer
|Cancer Cell|2018|251
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|Journal of Hematology & Oncology|2016|250
Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study
|The Lancet Infectious Diseases|2015|231